APA (7th ed.) Citation

E, L., FM, H., N, C., O, H., GF, F., R, N., . . . H, Y. (2026). Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 32(4), 641. https://doi.org/10.1177/10781552241305417

Chicago Style (17th ed.) Citation

E, Ly, Howard FM, Chen N, Hahn O, Fleming GF, Nanda R, Patel S, Thimothy L, and Yang H. "Evaluation of Cyclin-dependent Kinase 4/6 Inhibitor-induced Serum Creatinine Elevations in Patients with Hormone Receptor Positive Breast Cancer." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners 32, no. 4 (2026): 641. https://doi.org/10.1177/10781552241305417.

MLA (9th ed.) Citation

E, Ly, et al. "Evaluation of Cyclin-dependent Kinase 4/6 Inhibitor-induced Serum Creatinine Elevations in Patients with Hormone Receptor Positive Breast Cancer." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, vol. 32, no. 4, 2026, p. 641, https://doi.org/10.1177/10781552241305417.